Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
JAMA. 2019 Mar 12;321(10):969-982. doi: 10.1001/jama.2019.1347.
An American Academy of Orthopaedic Surgeons guideline recommends tramadol for patients with knee osteoarthritis, and an American College of Rheumatology guideline conditionally recommends tramadol as first-line therapy for patients with knee osteoarthritis, along with nonsteroidal anti-inflammatory drugs.
To examine the association of tramadol prescription with all-cause mortality among patients with osteoarthritis.
DESIGN, SETTING, AND PARTICIPANTS: Sequential, propensity score-matched cohort study at a general practice in the United Kingdom. Individuals aged at least 50 years with a diagnosis of osteoarthritis in the Health Improvement Network database from January 2000 to December 2015, with follow-up to December 2016.
Initial prescription of tramadol (n = 44 451), naproxen (n = 12 397), diclofenac (n = 6512), celecoxib (n = 5674), etoricoxib (n = 2946), or codeine (n = 16 922).
All-cause mortality within 1 year after initial tramadol prescription, compared with 5 other pain relief medications.
After propensity score matching, 88 902 patients were included (mean [SD] age, 70.1 [9.5] years; 61.2% were women). During the 1-year follow-up, 278 deaths (23.5/1000 person-years) occurred in the tramadol cohort and 164 (13.8/1000 person-years) occurred in the naproxen cohort (rate difference, 9.7 deaths/1000 person-years [95% CI, 6.3-13.2]; hazard ratio [HR], 1.71 [95% CI, 1.41-2.07]), and mortality was higher for tramadol compared with diclofenac (36.2/1000 vs 19.2/1000 person-years; HR, 1.88 [95% CI, 1.51-2.35]). Tramadol was also associated with a higher all-cause mortality rate compared with celecoxib (31.2/1000 vs 18.4/1000 person-years; HR, 1.70 [95% CI, 1.33-2.17]) and etoricoxib (25.7/1000 vs 12.8/1000 person-years; HR, 2.04 [95% CI, 1.37-3.03]). No statistically significant difference in all-cause mortality was observed between tramadol and codeine (32.2/1000 vs 34.6/1000 person-years; HR, 0.94 [95% CI, 0.83-1.05]).
Among patients aged 50 years and older with osteoarthritis, initial prescription of tramadol was associated with a significantly higher rate of mortality over 1 year of follow-up compared with commonly prescribed nonsteroidal anti-inflammatory drugs, but not compared with codeine. However, these findings may be susceptible to confounding by indication, and further research is needed to determine if this association is causal.
美国矫形外科医师学会指南建议将曲马多用于膝骨关节炎患者,而美国风湿病学会指南有条件地建议将曲马多作为膝骨关节炎患者的一线治疗药物,与非甾体抗炎药一起使用。
研究曲马多处方与骨关节炎患者全因死亡率之间的关联。
设计、地点和参与者:在英国的一家普通诊所进行的连续、倾向评分匹配队列研究。在健康改善网络数据库中,2000 年 1 月至 2015 年 12 月期间年龄至少 50 岁、诊断为骨关节炎的个体,随访至 2016 年 12 月。
曲马多(n=44451)、萘普生(n=12397)、双氯芬酸(n=6512)、塞来昔布(n=5674)、依托考昔(n=2946)或可待因(n=16922)的初始处方。
与其他 5 种止痛药物相比,曲马多初始处方后 1 年内的全因死亡率。
在倾向评分匹配后,纳入了 88902 名患者(平均[SD]年龄,70.1[9.5]岁;61.2%为女性)。在 1 年的随访期间,曲马多组发生 278 例死亡(23.5/1000人年),萘普生组发生 164 例(13.8/1000 人年)(率差,9.7 例/1000 人年[95%CI,6.3-13.2];风险比[HR],1.71[95%CI,1.41-2.07]),与双氯芬酸相比,曲马多的死亡率更高(36.2/1000 与 19.2/1000 人年;HR,1.88[95%CI,1.51-2.35])。与塞来昔布(31.2/1000 与 18.4/1000 人年;HR,1.70[95%CI,1.33-2.17])和依托考昔(25.7/1000 与 12.8/1000 人年;HR,2.04[95%CI,1.37-3.03])相比,曲马多也与全因死亡率较高相关。与可待因(32.2/1000 与 34.6/1000 人年;HR,0.94[95%CI,0.83-1.05])相比,曲马多与全因死亡率无统计学显著差异。
在年龄在 50 岁及以上的骨关节炎患者中,与常用的非甾体抗炎药相比,曲马多的初始处方与 1 年随访期间的死亡率显著升高相关,但与可待因相比则无显著差异。然而,这些发现可能容易受到指示性偏倚的影响,需要进一步研究来确定这种关联是否具有因果关系。